vs
Community Healthcare Trust Inc（CHCT）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Community Healthcare Trust Inc的季度营收约是STANDARD BIOTOOLS INC.的1.6倍（$30.9M vs $19.6M），Community Healthcare Trust Inc净利率更高（46.6% vs -177.4%，领先224.0%），Community Healthcare Trust Inc同比增速更快（5.6% vs -11.5%），Community Healthcare Trust Inc自由现金流更多（$35.9M vs $-23.1M），过去两年Community Healthcare Trust Inc的营收复合增速更高（2.7% vs -12.2%）
医疗物业信托（MPT）是一家总部位于美国阿拉巴马州伯明翰的国际房地产投资信托（REIT）企业，主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司多数物业收购以售后回租形式完成：原物业所有者将物业出售给MPT后，转而成为MPT的租户，租户通常签订长期三净租赁合约。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CHCT vs LAB — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.9M | $19.6M |
| 净利润 | $14.4M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | — | -168.5% |
| 净利率 | 46.6% | -177.4% |
| 营收同比 | 5.6% | -11.5% |
| 净利润同比 | 687.6% | -28.8% |
| 每股收益（稀释后） | $0.52 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $30.9M | — | ||
| Q3 25 | $31.1M | $19.6M | ||
| Q2 25 | $29.1M | $21.8M | ||
| Q1 25 | $30.1M | $40.8M | ||
| Q4 24 | $29.3M | — | ||
| Q3 24 | $29.6M | $22.1M | ||
| Q2 24 | $27.5M | $22.5M | ||
| Q1 24 | $29.3M | $45.5M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $1.6M | $-34.7M | ||
| Q2 25 | $-12.6M | $-33.5M | ||
| Q1 25 | $1.6M | $-26.0M | ||
| Q4 24 | $1.8M | — | ||
| Q3 24 | $1.7M | $-26.9M | ||
| Q2 24 | $-10.4M | $-45.7M | ||
| Q1 24 | $3.7M | $-32.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% |
| Q4 25 | 46.6% | — | ||
| Q3 25 | 5.3% | -177.4% | ||
| Q2 25 | -43.2% | -153.7% | ||
| Q1 25 | 5.3% | -63.8% | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 5.9% | -122.0% | ||
| Q2 24 | -37.9% | -203.3% | ||
| Q1 24 | 12.5% | -70.6% |
| Q4 25 | $0.52 | — | ||
| Q3 25 | $0.03 | $-0.09 | ||
| Q2 25 | $-0.50 | $-0.09 | ||
| Q1 25 | $0.03 | $-0.07 | ||
| Q4 24 | $0.04 | — | ||
| Q3 24 | $0.04 | $-0.07 | ||
| Q2 24 | $-0.42 | $-0.12 | ||
| Q1 24 | $0.11 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $129.4M |
| 总债务越低越好 | $532.2M | — |
| 股东权益账面价值 | $429.4M | $399.7M |
| 总资产 | $990.8M | $539.6M |
| 负债/权益比越低杠杆越低 | 1.24× | — |
8季度趋势，按日历期对齐
| Q4 25 | $3.3M | — | ||
| Q3 25 | $3.4M | $129.4M | ||
| Q2 25 | $4.9M | $158.6M | ||
| Q1 25 | $2.3M | $150.9M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $2.8M | $210.6M | ||
| Q2 24 | $734.0K | $269.8M | ||
| Q1 24 | $3.8M | $287.1M |
| Q4 25 | $532.2M | — | ||
| Q3 25 | $530.1M | — | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | — | ||
| Q3 24 | $473.7M | $55.2M | ||
| Q2 24 | $457.6M | $55.1M | ||
| Q1 24 | $442.3M | $55.0M |
| Q4 25 | $429.4M | — | ||
| Q3 25 | $426.8M | $399.7M | ||
| Q2 25 | $437.8M | $424.5M | ||
| Q1 25 | $461.3M | $454.6M | ||
| Q4 24 | $476.0M | — | ||
| Q3 24 | $477.2M | $489.3M | ||
| Q2 24 | $497.8M | $510.3M | ||
| Q1 24 | $511.6M | $577.3M |
| Q4 25 | $990.8M | — | ||
| Q3 25 | $987.3M | $539.6M | ||
| Q2 25 | $966.3M | $557.0M | ||
| Q1 25 | $985.1M | $579.6M | ||
| Q4 24 | $992.6M | — | ||
| Q3 24 | $981.8M | $681.5M | ||
| Q2 24 | $983.2M | $708.7M | ||
| Q1 24 | $982.7M | $777.7M |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.99× | 0.11× | ||
| Q2 24 | 0.92× | 0.11× | ||
| Q1 24 | 0.86× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.4M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $35.9M | $-23.1M |
| 自由现金流率自由现金流/营收 | 116.0% | -118.1% |
| 资本支出强度资本支出/营收 | 66.3% | 4.5% |
| 现金转化率经营现金流/净利润 | 3.91× | — |
| 过去12个月自由现金流最近4个季度 | $62.8M | $-111.1M |
8季度趋势，按日历期对齐
| Q4 25 | $56.4M | — | ||
| Q3 25 | $12.7M | $-22.2M | ||
| Q2 25 | $13.8M | $-20.7M | ||
| Q1 25 | $14.4M | $-30.3M | ||
| Q4 24 | $58.9M | — | ||
| Q3 24 | $13.8M | $-27.9M | ||
| Q2 24 | $16.7M | $-39.0M | ||
| Q1 24 | $12.6M | $-62.5M |
| Q4 25 | $35.9M | — | ||
| Q3 25 | $7.6M | $-23.1M | ||
| Q2 25 | $9.6M | $-22.6M | ||
| Q1 25 | $9.7M | $-35.3M | ||
| Q4 24 | $34.2M | — | ||
| Q3 24 | $6.7M | $-30.1M | ||
| Q2 24 | $9.5M | $-41.0M | ||
| Q1 24 | $7.5M | $-63.3M |
| Q4 25 | 116.0% | — | ||
| Q3 25 | 24.6% | -118.1% | ||
| Q2 25 | 32.9% | -103.6% | ||
| Q1 25 | 32.3% | -86.6% | ||
| Q4 24 | 116.9% | — | ||
| Q3 24 | 22.5% | -136.4% | ||
| Q2 24 | 34.7% | -182.2% | ||
| Q1 24 | 25.7% | -138.9% |
| Q4 25 | 66.3% | — | ||
| Q3 25 | 16.3% | 4.5% | ||
| Q2 25 | 14.5% | 8.7% | ||
| Q1 25 | 15.6% | 12.4% | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 24.2% | 10.2% | ||
| Q2 24 | 26.1% | 8.6% | ||
| Q1 24 | 17.4% | 1.7% |
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHCT
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
